1. Draw 0.5 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label and refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe.

AOD-9604 is a modified C-terminal fragment of human growth hormone that retains the lipolytic (fat-reducing) domain without the growth-promoting effects. It binds to adipose tissue and triggers breakdown of stored fat while blocking new fat storage (re-esterification) in adipocytes. At the molecular level, chronic AOD-9604 administration upregulates b3-adrenergic receptors in fat tissue, reversing obesity-related suppression of these fat-burning receptors. Unlike full-length hGH, AOD-9604 does not meaningfully elevate IGF-1 levels or worsen glucose tolerance, making its tolerability indistinguishable from placebo in human trials.

• Supports reductions in fat mass and increases in fat oxidation over time; clinical trials showed modest but
  statistically significant weight loss (approximately 2.6 kg vs. 0.8 kg placebo over 12 weeks at 1 mg/day).
• Preferential loss of abdominal fat observed, resembling the pattern seen with low-dose hGH therapy.
  Does not meaningfully raise IGF-1 and shows a placebo-like safety profile in human studies; no
  anti-AOD9604 antibodies detected.
• Emerging regenerative potential: preclinical studies suggest possible cartilage repair and bone health
  benefits.
• Generally well tolerated; occasional mild injection-site reactions (redness, itch) may occur with
  subcutaneous administration.